Evidence map›Paper›PMID 33924524›Full record

ReviewGenes2021

Cystic Fibrosis Lung Disease Modifiers and Their Relevance in the New Era of Precision Medicine.

Afsoon Sepahzad, Deborah J Morris-Rosendahl, Jane C Davies

Open access · goldAbstract readReview
In one paragraph

Review in Genes, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
4.1field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 33 citations in OpenAlex.

  1. Article
  2. Review
  3. Role of theInternational journal of molecular sciences · 2025
    Article
  4. Review
  5. Review
  6. LMTK2 switches on canonical TGF-β1 signaling in human bronchial epithelial cells.American journal of physiology. Lung cellular and molecular physiology · 2024
    Article
  7. Article
  8. Review
  9. Review
  10. Review
  11. Review
  12. Children (Basel, Switzerland) · 2023
    Article
  13. Review
  14. Modifier Factors of Cystic Fibrosis Phenotypes: A Focus on Modifier Genes.International journal of molecular sciences · 2022
    Review
  15. Review
  16. A year in review: Real world evidence, functional monitoring and emerging therapeutics in 2021.Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society · 2022
    Review
  17. Article
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Afsoon SepahzadDepartment of Paediatric Respiratory Medicine, Royal Brompton and Harefield Hospitals, London SW3 6NP, UK.
Deborah J Morris-RosendahlClinical Genetics and Genomics Laboratory, Royal Brompton and Harefield Hospitals, London SW3 6NP, UK.ORCID 0000-0002-7780-4707
Jane C DaviesDepartment of Paediatric Respiratory Medicine, Royal Brompton and Harefield Hospitals, London SW3 6NP, UK.
Harefield Hospital · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Our understanding of cystic fibrosis (CF) has grown exponentially since the discovery of the cystic fibrosis transmembrane conductance regulator (

Indexed as

Genes, ModifierCystic FibrosisCystic Fibrosis Transmembrane Conductance RegulatorGenome-Wide Association StudyHumansMutationCFTR protein, humanCystic Fibrosis Transmembrane Conductance Regulatorcystic fibrosislungmodifier genes

Identifiers

PMID33924524
PMCPMC8069009
OpenAlexW3154770924

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.